Anti-PD-1 inhibitors have been extensively studied and have shown promise in treating solid tumors, including non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), urothelial cancer and hepatocellular carcinoma [28,29,30,31]. This evidence concerns the gene PDCD1 and hereditary clear cell renal cell carcinoma.